决奈达隆
医学
胺碘酮
心房扑动
心房颤动
心脏病学
内科学
纤颤
作者
Yihong Sun,C S,Shulin Wu
出处
期刊:PubMed
日期:2021-12-01
卷期号:60 (12): 1139-1147
标识
DOI:10.3760/cma.j.cn112138-20210505-00326
摘要
Dronedarone, a class Ⅲ antiarrhythmic drug, is a deiodinated benzofuran derivative of amiodarone. It has similar antiarrhythmic effects with amiodarone, but much lesser adverse effects than amiodarone, particularly in those outside the heart. It is suggested to use dronedarone for the rhythm control of atrial fibrillation/flutter, for it has been shown to prevent the recurrence of atrial fibrillation/flutter and reduce rehospitalization in patients with paroxysmal or persistent atrial fibrillation/flutter. Dronedarone is not recommended for the rhythm control in patients with long-term persistent atrial fibrillation or permanent atrial fibrillation, and atrial flutter or atrial fibrillation patients with reduced ejection fraction. Liver function, electrolyte tests and an electrocardiogram should be performed before and after the drug initiation. Potential interactions with other kinds of drugs have to be taken into consideration as well.决奈达隆是Ⅲ类抗心律失常药物,一种脱碘的苯并呋喃衍生物,其抗心律失常作用机制与胺碘酮类似,但不良反应明显减少。决奈达隆主要用于阵发性或持续性心房颤动(房颤)/心房扑动(房扑)患者的节律控制,减少房颤/房扑的复发,并降低再住院风险。不建议决奈达隆用于长程持续性房颤或永久性房颤,以及射血分数减低的房扑或房颤患者。在治疗过程中应该规律监测心电图、电解质和肝肾功能,并注意与其他药物的相互作用。.
科研通智能强力驱动
Strongly Powered by AbleSci AI